Loading…

Classifying anatomical subtypes of subjective memory impairment

Abstract We aimed to categorize subjective memory impairment (SMI) individuals based on their patterns of cortical thickness and to propose simple models that can classify each subtype. We recruited 613 SMI individuals and 613 age- and gender-matched normal controls. Using hierarchical agglomerative...

Full description

Saved in:
Bibliographic Details
Published in:Neurobiology of aging 2016-12, Vol.48, p.53-60
Main Authors: Jung, Na-Yeon, Seo, Sang Won, Yoo, Heejin, Yang, Jin-Ju, Park, Seongbeom, Kim, Yeo Jin, Lee, Juyoun, Lee, Jin San, Jang, Young Kyoung, Lee, Jong Min, Kim, Sung Tae, Kim, Seonwoo, Kim, Eun-Joo, Na, Duk L, Kim, Hee Jin
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract We aimed to categorize subjective memory impairment (SMI) individuals based on their patterns of cortical thickness and to propose simple models that can classify each subtype. We recruited 613 SMI individuals and 613 age- and gender-matched normal controls. Using hierarchical agglomerative cluster analysis, SMI individuals were divided into three subtypes: Temporal atrophy (12.9%), Minimal atrophy (52.4%), and Diffuse atrophy (34.6%). Individuals in the Temporal atrophy (AD-like atrophy) subtype were older, had more vascular risk factors, and scored the lowest on neuropsychological tests. Combination of these factors classified the Temporal atrophy subtype with 73.2% accuracy. On the other hand, individuals with the Minimal atrophy (non-neurodegenerative) subtype were younger, were more likely to be female, and had depression. Combination of these factors discriminated the Minimal atrophy subtype with 76.0% accuracy. We suggest that SMI can be largely categorized into three anatomical subtypes that have distinct clinical features. Our models may help physicians decide next steps when encountering SMI patients and may also be used in clinical trials.
ISSN:0197-4580
1558-1497
DOI:10.1016/j.neurobiolaging.2016.08.010